Cart
sales@molnova.com
WAY-311610
CAS No. 314051-55-3
WAY-311610( —— )
Catalog No. M36983 CAS No. 314051-55-3
WAY-311610 is an 11β-hydroxysteroid dehydrogenase HSD11B1 inhibitor that inhibits the 11β-HSD1 enzyme with an IC = 0.34 μM.It can be used to study neuropathic pain, inflammatory pain, and occipital neuralgia.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 245 | In Stock |
|
| 10MG | 363 | In Stock |
|
| 25MG | 562 | In Stock |
|
| 50MG | 759 | In Stock |
|
| 100MG | 1014 | In Stock |
|
| 200MG | 1376 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameWAY-311610
-
NoteResearch use only, not for human use.
-
Brief DescriptionWAY-311610 is an 11β-hydroxysteroid dehydrogenase HSD11B1 inhibitor that inhibits the 11β-HSD1 enzyme with an IC = 0.34 μM.It can be used to study neuropathic pain, inflammatory pain, and occipital neuralgia.
-
DescriptionWAY-311610 is an 11β-hydroxysteroid dehydrogenase HSD11B1 inhibitor that inhibits the 11β-HSD1 enzyme with an IC = 0.34 μM.It can be used to study neuropathic pain, inflammatory pain, and occipital neuralgia.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayMetabolic Enzyme/Protease
-
TargetDehydrogenase
-
RecptorDehydrogenase
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number314051-55-3
-
Formula Weight350.3
-
Molecular FormulaC16H13F3N4O2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC(F)(F)(F)C=1N2C(N=C(C1)C3=CC=CO3)=CC(C(=O)N4CCCC4)=N2
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
DHODH-IN-14
DHODH-IN-14 is an analog of hydroxyfuran pyrimidine A771726.
-
ALDH2 modulator 1
ALDH2 modulator 1 is a potent, orally active modulator of acetaldehyde dehydrogenase-2 (ALDH2), which reduces blood alcohol levels in mice.
-
IDH2R140Q-IN-2
IDH2R140Q-IN-2 is an orally active and potent IDH2R140Q inhibitor with an IC50 of 29 nM.IDH2R140Q-IN-2 possesses potential antitumour activity, reducing D2HG production in TF-1 cell lines carrying the IDH2R140Q mutation (IC50 of 10 nM) and inhibiting tumour tissue D2HG levels.
